BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.3733
-0.0193 (-4.92%)
At close: Mar 28, 2025, 4:00 PM
0.3695
-0.0038 (-1.03%)
After-hours: Mar 28, 2025, 7:56 PM EDT
BioAtla Revenue
In the year 2024, BioAtla had annual revenue of $11.00M.
Revenue (ttm)
$11.00M
Revenue Growth
n/a
P/S Ratio
1.64
Revenue / Employee
$169,231
Employees
65
Market Cap
21.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BCAB News
- 3 days ago - BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - BioAtla Cuts 30% of Jobs in Restructuring Effort - Market Watch
- 3 days ago - BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 10 days ago - BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - GlobeNewsWire
- 11 days ago - BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - GlobeNewsWire
- 26 days ago - AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology) - GlobeNewsWire
- 3 months ago - BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points - GlobeNewsWire
- 3 months ago - BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - GlobeNewsWire